What is the goal of using GnRH agonists in the treatment of endometriosis?

• A. To decrease progesterone levels
• B. To induce a hypoestrogenic state
• C. To promote ovulation
• D. To increase estrogen production

Answer: (B)

The goal of using GnRH agonists in the treatment of endometriosis is to induce a hypoestrogenic state. GnRH (gonadotropin-releasing hormone) agonists function by initially stimulating the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn leads to increased production of estrogen and progesterone from the ovaries. However, with prolonged administration, these agonists cause downregulation of GnRH receptors, leading to reduced secretion of LH and FSH. This ultimately results in decreased ovarian hormone production, specifically lowering estrogen levels significantly.

The hypoestrogenic state is crucial for the management of endometriosis because it reduces the estrogen-dependent growth of endometrial tissue. Many of the symptoms associated with endometriosis are exacerbated by estrogen, so by minimizing estrogen levels, the growth and activity of endometriotic lesions are suppressed, which can alleviate pain and other related symptoms.

Other options, such as decreasing progesterone levels, promoting ovulation, or increasing estrogen production, do not align with the therapeutic objective of GnRH agonists in endometriosis treatment.